Foley Partner David Simon will join Sherbir Panag, of the Law Offices of Panag & Babu in India; Eike Grunert, of Pinsent Masons in the UK; and Jason Sugarman, of Foundry Chambers in the UK in a webinar presented by Mondaq Webinars, entitled “Global Investigations During the Covid 19 Pandemic.”
The COVID-19 pandemic has had an impact on nearly all aspects of businesses and governments around the world, including the conduct of internal investigations and law enforcement actions, but taking steps to remain fully compliant with policy and law has been further complicated by inconsistencies in enforcement from one jurisdiction to the next. In some jurisdictions, we have noted a continued slowdown in law enforcement activity, while in others we are seeing a relative return to normalcy. The challenge at the heart of the pandemic, given this range of official responses, is that while law enforcement may not be as visible, the expectations of governance, compliance, self-reporting, or response to criminal misconduct remain largely unchanged.
Providence and lessons from the 2008 financial crisis have provided some useful insights on how criminal misconduct risks, including increased fraud and bribery, intertwine with pandemic-related business disruption. Against this backdrop, our expert panel – covering the United States, United Kingdom, Germany, and India – will discuss how internal investigations and law enforcement expectations may have changed, how companies should respond to such issues in the new normal, and suggest best practices to mitigate or avoid government investigations.
There is no charge to attend this event. Register by clicking here.
People
Related Insights
April 23, 2026
Health Care Law Today
DEA Issues Long Awaited Final Order Rescheduling Certain Marijuana Products to Schedule III: What It Means, What It Doesn’t, and What Comes Next
Effective April 22, 2026, the Acting Attorney General issued a final order placing certain categories of marijuana and marijuana products into Schedule III of the Controlled Substances Act (“CSA”) in accordance with President Trump’s December 18, 2025 Executive Order on Increasing Medical Marijuana and Cannabidiol Research. This is a landmark development in federal drug policy and one that carries significant legal and business consequences for entities in the pharmaceutical, cannabis, healthcare, tax, and regulatory compliance sectors. As with most everything touching marijuana, however, the details matter enormously. Importantly, the Final Order does not broadly reclassify marijuana. Instead, it defines a narrow and conditional rescheduling that includes several important caveats, added steps, and ongoing obligations that affected parties must understand.
April 23, 2026
The Path & The Practice
Episode 136: Chanley Howell, Partner
This episode features a conversation with Chanley Howell. Chanley is a partner and intellectual property lawyer in Foley’s Jacksonville office where his practice focuses on a broad range of technology law matters. In this discussion, he reflects on growing up in Jacksonville, FL, attending Vanderbilt University for undergrad and the University of Florida College of Law.
April 23, 2026
Video
Ten Minute Interview: Alternative Investments
Brian Lucareli, director of Foley Private Client Services (PCS) and co-chair of the Family Offices team, sits down with Nick Chamis, senior counsel in the Estate Planning practice, for a 10-minute interview on alternative investments in the family office space.